Filter by year
-
august112020
Newron Pharmaceuticals provides clinical and business update
-
may292020
Newron Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
-
may42020
Newron Reports Top-Line Results from its STARS Study Evaluating Sarizotan in Patients with Rett Syndrome
-
april292020
Newron Acknowledges Definitive Agreement Between US WorldMeds and Supernus Pharmaceuticals Regarding XADAGO® (safinamide)
-
april152020
Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB)
-
march312020
Newron AGM Result and Clinical and Business Update
-
march112020
Newron updates on STARS study FDA interaction
-
march52020
Newron announces 2019 financial results and provides outlook for 2020
-
february172020
Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia
-
february42020
Newron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New York
-
january92020
Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA